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We previously described envelope glycoproteins of an HIV-1 isolate adapted in vitro for growth in microglia that acquired a highly fusogenic
phenotype and lower CD4 dependence, as well as resistance to inhibition by anti-CD4 antibodies. Here, we investigated whether similar
phenotypic changes are present in vivo. Envelope clones from the brain and spleen of an HIV-1-infected individual with neurological disease were
amplified, cloned, and sequenced. Phylogenetic analysis demonstrated clustering of sequences according to the tissue of origin, as expected.
Functional clones were then used in cell-to-cell fusion assays to test for CD4 and co-receptor utilization and for sensitivity to various antibodies
and inhibitors. Both brain- and spleen-derived envelope clones mediated fusion in cells expressing both CD4 and CCR5 and brain envelopes also
used CCR3 as co-receptor. We found that the brain envelopes had a lower CD4 dependence, since they efficiently mediated fusion in the presence
of low levels of CD4 on the target cell membrane, and they were significantly more resistant to blocking by anti-CD4 antibodies than the spleen-
derived envelopes. In contrast, we observed no difference in sensitivity to the CCR5 antagonist TAK-779. However, brain-derived envelopes were
significantly more resistant than those from spleen to the fusion inhibitor T-1249 and concurrently showed slightly greater fusogenicity. Our
results suggest an increased affinity for CD4 of brain-derived envelopes that may have originated from in vivo adaptation to replication in
microglial cells. Interestingly, we note the presence of envelopes more resistant to a fusion inhibitor in the brain of an untreated, HIV-1-infected
individual.
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Human immunodeficiency virus type 1 (HIV-1) enters the
central nervous system (CNS) early after systemic infection
(An et al., 1999; Davis et al., 1992) and may cause a
neurological disease ranging in severity from a minor
cognitive/motor disorder to severe dementia (McArthur et al.,
2003; Sacktor et al., 2002). Viral entry in the CNS is thought to0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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to replenish the population of perivascular macrophages.
Accordingly, productive infection in the brain has been shown
to occur in microglia (resident brain macrophages) and in
perivascular macrophages (Gonza´lez-Scarano and Martı´n-
Garcı´a, 2005), although these cell types express low levels of
the primary receptor for HIV-1: CD4 (Dick et al., 1997; Jordan
et al., 1991; Peudenier et al., 1991a, 1991b). In addition,
microglia are very long-lived cells (Hickey et al., 1992; Krall et
al., 1994; Unger et al., 1993), and it is believed that HIV-1 may
adapt in vivo to replication in microglial cells and macrophages
in the brain. The presence of multinucleated giant cells or
syncytia resulting from fusion of infected and uninfected cells
is the hallmark pathological finding in HIV or giant-cell
encephalitis (Sharer et al., 1985, 1986; Wiley et al., 1986).6) 169 – 179
www.e
Fig. 1. Phylogenetic reconstruction using Neighbor-Joining method (with
absolute distances) of ClustalW-aligned brain (BR)- and spleen (SPL)-derived
envelope clones. High bootstrap values in all branches supported the topology
of the tree, confirming compartmentalization of sequences according to the
tissue of origin.
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peripheral HIV-1 isolate for replication in cultures of pure
human adult microglial cells generated a highly syncytia-
inducing virus (Strizki et al., 1996). We demonstrated that the
viral envelope glycoproteins (gp120 and gp41) were respon-
sible for this phenotype (Martı´n et al., 2001; Shieh et al.,
2000), conferring (i) increased ability to use low levels of CD4
for infection; (ii) increased exposure of the CD4-induced
(CD4i) epitope that is recognized by the 17b monoclonal
antibody (MAb), which collocates with the chemokine receptor
binding site, and (iii) increased sensitivity to neutralization by
the 17b MAb as well as by HIV-1-positive sera. We also found
that the soluble, monomeric gp120 of the microglia-adapted
virus had a higher affinity in its interaction with CD4 and with
Abs to CD4-induced epitopes, mainly due to very low
dissociation rates. This increased affinity correlated with
decreased sensitivity to inhibition of infection by anti-CD4
MAbs in the context of viral particles, which were used as a
surrogate for the CD4:trimeric envelope interaction (Martı´n-
Garcı´a et al., 2005). In summary, our results suggested that
viruses with envelopes with lower CD4 dependence, altered
glycosylation, and partially triggered conformation may arise
in the CNS as a result of adaptation to replication in microglial
cells, resulting in a more stable interaction with CD4 and an
increase in fitness for the target cell population in this specific
niche.
Many studies have performed genetic comparisons of
various HIV-1 genes obtained from the CNS and peripheral
tissues of the same individuals (Epstein et al., 1991; Kodama et
al., 1993; Korber et al., 1994; Reddy et al., 1996; Wong et al.,
1997). However, until recently, there had not been any
information regarding the phenotypic characterization of paired
primary isolates or envelope glycoproteins from the brain and
peripheral tissues. In this regard, Gabuzda and colleagues
reported no major phenotypic differences—in terms of
glycosylation sites, co-receptor usage, or binding to various
Abs—between brain- and lymphoid tissue-derived envelopes
(Ohagen et al., 2003). More recently, Clapham and co-workers
described no difference in co-receptor usage between brain-
and lymph node-derived envelopes but showed that the
macrophage tropism of brain-derived envelopes correlated
with reduced sensitivity to inhibition by an anti-CD4 MAb
but not by the CCR5 antagonist TAK-779, and with increased
ability to infect cells expressing low levels of CD4 and/or
CCR5 (Peters et al., 2004).
In this study, we confirmed that envelope glycoproteins
derived from the brain of one individual with HIV-1-
associated neurological disease have lower CD4 dependence
and higher CD4 affinity than spleen-derived envelopes, since
they efficiently mediated fusion with target cells expressing
low levels of CD4, and they had significantly reduced
sensitivity to inhibition by several anti-CD4 MAbs. However,
we also found an increased usage of CCR3 as co-receptor, in
addition to CCR5, in brain- versus spleen-derived envelopes.
More importantly, we also demonstrated that the brain-derived
envelopes had a significantly lower sensitivity to the second
generation fusion inhibitor T-1249 and had slightly greaterfusogenicity, even though there was no difference in CCR5
dependence or in the sensitivity to the anti-CCR5 antagonist
TAK-779. Changes in the amino acid sequence in the
carboxy-terminal heptad repeat region (HR2) of the gp41
ectodomain (gp41e), but not in the amino-terminal HR1, and
throughout the variable regions of gp120 (mainly V1/V2, V3
and V4), may be responsible for the observed phenotypic
discrepancies.
Results and discussion
We obtained brain and spleen autopsy tissue from an HIV-1-
positive, untreated individual with neurological disease as
indicated in Materials and methods. Total DNA was isolated
from tissue samples, and the envelope genes were PCR-
amplified, cloned, and sequenced as previously described
(Shieh et al., 2000). We obtained 6 envelope clones from each
tissue and their sequences have been deposited into GenBank
(accession numbers DQ222210–DQ222221). Among the brain
clones, 2 of them lack a stop codon, and another one has a stop
codon just before the transmembrane domain in gp41, making
these 3 non-functional. Of the spleen-derived clones, only one
has an early stop codon, and thus, we had a set of 3 brain
clones and 5 spleen clones with open reading frames which
were considered potentially functional. As expected, sequence
alignment and phylogenetic reconstruction of potentially
functional envelope clones (performed using the Discovery
Studio Gene software package) showed compartmentalization
of sequences, since the envelope clones from the brain
clustered separately from the spleen-derived clones (Fig. 1).
The phylogenetic tree was supported by high scores in
bootstrap analysis.
We also examined the gp120 and gp41 regions of known
relevance for some of the key functional characteristics of the
HIV-1 envelope glycoproteins. We found that the brain- and
spleen-derived clones differed at multiple sites throughout the
variable regions V1/V2, V3, and V4 in gp120, as well as in
the HR2 region of the gp41e, though not in HR1 (Fig. 2).
The total number of potential glycosylation sites was similar
in all clones (28 in BR4 and BR7, 26 in BR8; 27 in SPL2,
SPL3, SPL9, and SPL18, 28 in SPL12). The exact number
and position of glycosylation sites in or around variable
Fig. 2. Amino acid differences between brain and spleen envelope clones. Changes in the highly variable regions of gp120 (V1/V2, V3, and V4) and HR1 and HR2
regions in gp41 ectodomain are shown. Grey background denotes potential glycosylation site. Dots indicate no change with respect to the sequence of the HxB2
isolate (shown for reference). Hyphens indicate gap in the sequence. Highlighted in bold are residues within HR2 of brain-derived clones that, to our knowledge,
although in positions considered polymorphic (moderately to highly variable) in light of the HIV-1 sequence literature, have not been reported at all, or only in a very
small number of sequences.
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in V1/V2 and V3, was absolutely conserved in all spleen
clones, while those from brain had slightly greater variability.
Residues in gp120 that have been implicated in the
interaction with CD4 were all present in the potentially
functional clones. Except for a DYG change in one spleen-
derived clone, all brain and spleen clones had also identical
amino acid sequence in the HR1 region of gp41e. However,
six amino acid differences were found conserved between all
brain clones and all spleen clones in the HR2 region. These
changes are in residues with different degree of polymor-
phism according to the HIV-1 sequence literature, as dis-
cussed below.
All potentially functional envelope clones were then
subcloned into pcDNA3.1, a mammalian expression vector.
Transient transfection of these envelope clones into quail QT6
cells by calcium phosphate precipitation demonstrated that
only two clones per tissue (BR4 and BR7, SPL2, and SPL3)
were able to mediate fusion in cell-to-cell fusion assays. We
subsequently used the functional envelope clones to test for
receptor and co-receptor utilization as well as for sensitivity to
antibodies and to various inhibitors. There is an apparent
clustering in the phylogenetic reconstruction between func-
tional and non-functional envelope clones; however, due to the
small number of clones in each group, it is very difficult to
conclude whether there is a relationship between evolution of
these envelopes and functionality.CD4 and co-receptor utilization
We found that both brain-derived and spleen-derived
envelope clones required CD4 on the target cell membrane in
order to mediate cell-to-cell fusion, and that they used CCR5 as
co-receptor very efficiently. Previous experiments (Gorry et al.,
2002; Martı´n et al., 2001; Martı´n-Garcı´a et al., 2005; Peters et
al., 2004) have shown that envelopes with increased tropism
for microglia also mediate fusion/infection with target cells
expressing a low density of CD4 molecules on the cell
membrane. To test whether brain- and spleen-derived envel-
opes differed in their dependency for CD4 or CCR5, we
evaluated cell-to-cell fusion with target cells expressing these
receptors at various levels. The receptor density on the surface
of target cells was varied by transiently transfecting cells with
0.05, 0.5, or 5 Ag of plasmid DNA of CD4 and CCR5
expression vectors, and surface receptor expression was
determined by flow cytometric analysis of cells stained with
fluorochrome-conjugated anti-CD4 and anti-CCR5 Abs. As
shown in Supplementary material as Fig. 8, both the percentage
of cells with fluorescence above background levels (determined
with isotype control Abs and empty vector-transfected cells
stained with anti-CD4 or anti-CCR5 Abs), as well as the
fluorescence intensity, were directly related with the amount of
expression plasmid used in the transfection step.
Fig. 3 shows that the brain-derived envelopes mediated
fusion more efficiently than those from spleen when the target
Fig. 4. Co-receptor usage of brain- and spleen-derived envelopes. Envelope
mediated cell-to-cell fusion experiments were performed with target cells
expressing CD4 plus different chemokine receptors known to support HIV-1
envelope-mediated fusion and entry. Both brain- and spleen-derived envelopes
used CCR5 as the main co-receptor (shown as 100%). CXCR4 was not used to
detectable levels; however, brain-derived envelopes showed significantly
greater ability to use CCR3 as co-receptor than envelopes from the spleen
The mean T standard deviation of four independent experiments is shown
-, Student’s t test: P < 0.001, versus CCR3 usage by spleen-derived envelopes
Fig. 3. CD4 and CCR5 requirements of brain- and spleen-derived envelopes. Envelope-mediated cell-to-cell fusion experiments with target cells expressing various
levels of CD4 and CCR5 were performed. Brain-derived envelopes mediated fusion more efficiently than spleen envelopes with cells expressing low levels of CD4,
whereas the spleen-derived envelopes showed slightly better fusion than brain envelopes with cells expressing low levels of CCR5, but only in the presence of high
levels of CD4. Representative data of three independent experiments are shown. The results are presented as percentage of fusion relative to that observed with target
cells expressing high levels of CD4 and CCR5.
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expressing low levels of CCR5, the spleen-derived envelopes
were able to mediate fusion when CD4 was present at high
density, while the brain-derived envelopes could not. Our data
thus suggest, in agreement with Peters et al. (2004), that
envelopes amplified from the brain of HIV-1-positive indivi-
duals have lower CD4 dependence than those from spleen.
However, in this case, the spleen-derived envelopes had a
lower CCR5 dependence than those from the brain, at least in
the presence of high levels of CD4. In order to rule out
potential differences in the level of expression between
envelopes from brain and spleen as the reason for the observed
phenotypic change, we lysed cells transiently transfected with
envelope expression vectors or empty plasmid and determined
envelope levels by immunoassay as described in Materials and
methods. All envelopes were detected to similar levels, when
evaluated with either 17b MAb in the presence of excess
soluble CD4, or with IgG1 b12 MAb, as primary antibodies
(shown in Supplementary material as Fig. 9).
We also wanted to determine the pattern of co-receptor
usage of envelopes obtained from the brain and the spleen.
Although it is clear that CCR5 is the principal co-receptor used
by HIV-1 isolates in the CNS, the use of additional co-receptors
has been implicated in broadening viral tropism for other cell
types in the brain, and it might have implications for HIV
pathogenesis (Martı´n-Garcı´a et al., 2002; Neil et al., 2005).
Thus, we evaluated the extent to which various co-receptors
were used by these envelopes to mediate cell-to-cell fusion in
the presence of CD4. Firstly, we found that neither the brain-
nor spleen-derived envelopes were able to use the other major
co-receptor, CXCR4 (Fig. 4), nor indeed most of several others
tested (data not shown) with the exception of the chemokine
receptor Apj, which was used by both brain- and spleen-
derived envelopes to similar extent. However, there was a
noticeable use of CCR3 as co-receptor, particularly by the
brain-derived envelopes that were able to induce significantly
greater levels of fusion in cells expressing CD4 plus CCR3
(with respect to those obtained in cells expressing CD4 plus
CCR5) than the envelopes from the spleen (Student’s t test, P <
0.01) (Fig. 4). CCR3 is expressed by microglia, neurons, and
astrocytes in normal and encephalitic brain, and it has beenshown to be more prominently expressed in children with
AIDS and in simian immunodeficiency virus-infected maca-
ques (van der Meer et al., 2000; Westmoreland et al., 1998; Xia
et al., 1998). In addition to the CNS, CCR3 is also expressed
by eosinophils, basophils, and even T lymphocytes in
peripheral tissues. The use of CCR3 as co-receptor by some
primary HIV-1 isolates or envelopes amplified from tissues,
both from CNS and the periphery, has been described
previously (Albright et al., 1999; Choe et al., 1996; Doranz
et al., 1996; Gorry et al., 2001; He et al., 1997; Ohagen et al.,
2003; Peters et al., 2004). It is unclear however why brain- and
spleen-derived envelopes in our study differ in the ability to use
CCR3 as co-receptor. It is possible that the CNS environment,
being an immunologically privileged site (Aloisi et al., 2000;
Carson et al., 1998; Lustig et al., 1999), may be particularly
favorable for its use by allowing conformational changes in the
envelope glycoproteins that would not be tolerated in other
tissues. In addition, chemokine receptors are known to be able
to adopt various conformations (Baribaud et al., 2001; Lee et
al., 1999a), as well as to form homo- and heterodimers
(Springael et al., 2005). These factors, to some extent,
determine the ability of chemokine receptors to function as-
.
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acid sequence differences, could potentially contribute to this
phenotype.
Brain-derived envelopes have increased affinity for CD4 but
not CCR5
We have recently shown that the envelope of the
aforementioned microglia-adapted isolate has an increased
affinity for CD4, as determined by binding studies with
soluble, monomeric gp120 proteins (Martı´n-Garcı´a et al.,
2005). This increased affinity was also shown to correlate
with a lower sensitivity to inhibition by anti-CD4 MAbs in
the context of viral particles. Similarly, we tested the
susceptibility of envelope-mediated cell-to-cell fusion to
inhibition by three mouse anti-human CD4 MAbs (SK3,
#21, and RPA-T4) that are known to interfere with the
binding of HIV-1 gp120 to CD4 thus inhibiting fusion and
entry. As shown in Figs. 5A–C, we found that the brain-
derived envelopes were less sensitive to inhibition by the anti-
CD4 MAbs than the spleen-derived envelopes from the sameFig. 5. Sensitivity to anti-CD4 MAbs and to the CCR5 antagonist TAK-779. The af
and CCR5 was estimated by evaluating the sensitivity of envelope-mediated cell-to-c
and by CCR5 antagonist TAK-779 (D), respectively. Inhibitors were added to target
expressing effector cells. Fusion mediated by brain-derived envelopes was more res
Non-linear regression analysis demonstrated that inhibition curves were statistically
estimated for brain-derived envelopes, compared to those from spleen, with all thre
observed between brain and spleen envelopes. Inhibition of fusion mediated by wel
Data from a representative experiment are shown. Experiments were repeated at leindividual. This is consistent with a greater affinity for CD4
and with increased ability to outcompete the binding of anti-
CD4 MAbs. Negative control mouse IgG had no effect on
cell-to-cell fusion (data not shown). In addition, other well-
characterized envelopes (YU-2, brain-derived isolate, and
Bori and BaL, peripheral blood isolates) were used in these
experiments and are shown for reference.
Non-linear regression analysis using a sigmoidal dose-
response model (variable slopes) demonstrated that the curves
showing anti-CD4 MAb inhibition of fusion mediated by
brain- and spleen-derived envelopes were statistically different,
since the null hypothesis of a single best-fit curve for all data
sets was rejected for all three antibodies (P < 0.0001 in all
cases). With all three MAbs, the 50% inhibitory concentrations
(IC50) estimated from non-linear regression analysis were
between 5.2- and 42-fold higher for the brain-derived
envelopes than for those from spleen (Table 1). Additionally,
we used Student’s t test to compare the IC50 values and
standard error obtained with non-linear regression analysis for
the brain and spleen envelopes and found that the differences
were also statistically significant (P < 0.01).finity of the interaction between brain- and spleen-derived envelopes with CD4
ell fusion to inhibition by anti-CD4 MAbs SK3 (A), #21 (B), and RPA-T4 (C),
cells expressing the receptors for 1 h prior to co-culturing them with envelope-
istant to inhibition by all three anti-CD4 mAbs than that by spleen envelopes.
different, and statistically significant, 5.2- to 42-fold higher IC50 values were
e anti-CD4 MAbs (see Table 1). No difference in inhibition by TAK-779 was
l-characterized control envelopes (YU-2, Bori and BaL) is shown for reference.
ast 3 times with similar results.
Table 1
IC50 values
a estimated by non-linear regression analysis for the inhibition of envelope-mediated cell-to-cell fusion by anti-CD4 antibodies and T-1249 fusion
inhibitor
Envelope SK3 anti-CD4 Ab #21 anti-CD4 Ab RPA-T4 anti-CD4 Ab T-1249
BR4 185.1 (120.8–283.5) 336.0 (168.2–671.3) 1013.3 (650.1–1579.5) 73.7 (54.0–100.7)
BR7 196.1 (132.1–291.3) 493.4 (286.7–848.7) 1542.0 (367.2–6478.5) 46.6 (36.2–60.0)
SPL2 26.4 (14.9–46.6) 23.5 (14.5–38.0) 36.6 (18.4–72.6) 9.5 (7.8–11.5)
SPL3 35.5 (23.1–54.5) 31.5 (25.8–38.5) 137.3 (73.0–258.5) 8.9 (7.7–10.3)
a IC50 values and 95% confidence intervals are expressed in ng/ml.
Fig. 6. Brain-derived envelopes are more resistant to the fusion inhibitor T
1249. The sensitivity of envelope-mediated cell-to-cell fusion to T-1249 was
measured by incubating effector cells for 1 h with various concentrations of the
inhibitor before overlaying them onto target cells expressing high levels of CD4
and CCR5. Brain-derived envelopes were more resistant than those from spleen
to inhibition by T-1249, since non-linear regression analysis demonstrated tha
inhibition curves were statistically different, and allowed us to estimate tha
envelopes from brain had 4.9- to 8.3-fold higher IC50s than those from spleen
(P < 0.01). T-1249 inhibition of fusion mediated by well-characterized contro
envelopes (YU-2, Bori, and BaL) is shown for reference. Data from a
representative experiment are shown. Experiments were repeated at least 4
times with similar results.
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low levels of CD4 on the target cell membrane, suggested an
increased affinity for CD4 of the brain-derived envelopes. The
difference may have originated from an in vivo adaptation to
replication in microglial cells, since these cells have low levels
of CD4 and can support HIV-1 replication for long periods of
time. The brain- and spleen-derived envelope clones have
amino acid changes in V1/V2, V3, and V4 variable regions of
gp120, some of them involving potential glycosylation sites
and charged amino acids, which may be involved in the
acquisition of the phenotypic difference.
We also tested whether these envelopes differed in their
interaction with the chemokine receptor CCR5 by analyzing
the sensitivity of cell-to-cell fusion to the CCR5 antagonist
TAK-779 (Baba et al., 1999; Dragic et al., 2000). Contrary to
the results with anti-CD4 MAbs, there was no difference in
the sensitivity to TAK-779 between the brain- and spleen-
derived envelopes (Fig. 5D), since non-linear regression
analysis demonstrated that the inhibition curves were statis-
tically indistinguishable. In addition, the brain- and spleen-
derived envelopes had similar sensitivity to TAK-779 than the
control envelopes, YU-2, Bori, and BaL. A recent study
proposed that brain-derived envelopes may also have lower
CCR5 dependence and/or increased affinity for CCR5,
although no difference in sensitivity to TAK-779 was found
(Peters et al., 2004). Our cell-to-cell fusion data with target
cells expressing various levels of CCR5 and in the presence
of increasing concentrations of TAK-779 suggest that the
interaction of this particular set of brain- and spleen-derived
envelopes with CCR5 is likely to be very similar, and that if
anything, there is a trend towards a lower CCR5 dependence
and lower sensitivity to TAK-779 in the envelopes from the
spleen. Contrary to CD4, CCR5 levels in microglia and
macrophages are comparable to those in other target cells for
HIV-1 such as CD4+ T-cells (Albright et al., 1999; Lee et al.,
1999b; Rottman et al., 1997; Tuttle et al., 1998; Wu et al.,
1997), and therefore, it is not surprising that there is no
specific adaptation to low CCR5 levels in envelopes derived
from the CNS.
Brain-derived envelopes have lower sensitivity to the fusion
inhibitor T-1249
In contrast to the results with TAK-779, we found that the
brain-derived envelopes were significantly more resistant than
the spleen-derived envelopes to the fusion inhibitor T-1249
(Fig. 6). The curves showing T-1249 inhibition of fusionmediated by the spleen and brain envelopes were statistically
different, as demonstrated by non-linear regression analysis
using a sigmoidal dose-response model (P < 0.0001). We
estimated that envelopes from the brain had 4.9- to 8.3-fold
higher IC50s than those from spleen (Table 1); these were also
statistically significant by Student’s t test (P < 0.01). A
similar trend was observed when comparing these results with
those of the control envelopes, since YU-2 had an interme-
diate sensitivity to T-1249 (between that of brain- and spleen-
derived envelopes), while peripheral envelopes Bori and BaL
were equally or more sensitive to T-1249 than spleen
envelopes.
T-1249 is a second generation peptide fusion inhibitor
(Eron et al., 2004; Lalezari et al., 2005) that, similar to
Enfuvirtide (formerly T-20 and DP178), interferes with the
formation of a fusion intermediate (six-helix bundle) in the
ectodomain of the transmembrane glycoprotein gp41 (Kilby
and Eron, 2003; LaBranche et al., 2001). Diminished
sensitivity to fusion inhibitors correlates with higher affinity-
t
t
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molecule CCR5 and with faster fusion kinetics (Reeves et
al., 2002, 2004). Since there was no apparent difference in the
envelope:CCR5 interaction between brain- and spleen-derived
envelopes, we evaluated the fusogenicity of envelopes in cell-
to-cell fusion assays by measuring luciferase activity at
various time points after mixing effector and target cells.
Fig. 7 shows that envelope clones from the brain mediated
slightly higher levels of fusion than the spleen counterparts,
whether the target cells had low or high levels of CD4.
However, it seems unlikely that this variation in fusogenicity
may be enough to account for the observed difference in
sensitivity to the fusion inhibitor T-1249.
Several groups have also shown that HIV-1 isolates
acquire resistance to fusion inhibitors primarily because of
mutations in the HR1 region of the gp41e, although their
sensitivity may also be modulated by interactions between
gp120 and the co-receptor molecules (Derdeyn et al., 2000,
2001; Heil et al., 2004; Menzo et al., 2004; Reeves et al.,
2002, 2004; Rimsky et al., 1998; Wei et al., 2002; Xu et al.,
2005). HR1 is the region that creates a hydrophobic groove
where synthetic peptide fusion inhibitors mimicking HR2
segments bind competitively and inhibit fusion (Chan et al.,
1997; Kliger et al., 2001). Conversely, the association
between reduced sensitivity to fusion inhibitors and mutationsFig. 7. Fusogenicity of brain- and spleen-derived envelopes. Effector cells
expressing brain- and spleen-derived envelopes were incubated for 30 min to 6
h with target cells expressing low (top) or high (bottom) levels of CD4 plus
high levels of CCR5. At each time point, cells were lysed, and luciferase
activity was measured in all lysates at the same time. Results are expressed as
relative fusion (luciferase activity), with the fusion after 6 h being considered
100%. Irrespective of the levels of CD4, brain-derived envelopes tended to
mediate higher levels of fusion than the spleen counterparts. Data are
representative of two independent experiments with similar results.in HR2 has rarely been reported and then always in the
presence of additional mutations within HR1 (Wei et al.,
2002; Xu et al., 2005). While there were no amino acid
differences in the HR1 region of gp41e between the spleen
and brain clones used in these experiments, HR2 contained
several amino acid changes (Fig. 2). Most of the these
involved residues that can be considered polymorphic
(moderately to highly variable) in light of the HIV-1 sequence
literature (Dorn et al., 2000; Hanna et al., 2002; Sanders et
al., 2002; Wei et al., 2002; Xu et al., 2005), although to our
knowledge, the specific amino acid residues present in brain-
derived clones at these positions (highlighted in bold in Fig.
2) have not ever been reported together, and some of them are
only found in a minuscule number of sequences.
As shown in Supplementary material as Fig. 10, 640N
(according to the HxB2 numbering system) has been found in
brain- but not blood-derived envelopes of one individual
(Ohagen et al., 2003), and while it is present in some clade A
and C envelopes, it is not frequent in clade B. 644N has been
found in both brain and blood envelopes of 2 individuals and is
relatively common, however, 648K is present in 89.6 and blood-
derived envelopes of 1 individual, and it is quite rare. The
remaining three residues, 655M, 662K, and 665T, have only
been reported to our knowledge in 1–2 sequences in the
database.
Thus, it is possible that the particular amino acid sequence
in the HR2 region of brain envelopes could result in an
alteration/improvement of the interaction between HR2 and
HR1, potentially making the fusion process more resistant to
the action of T-1249. In addition, the phenotypic changes
observed in the interaction with CD4 could also be modulating
the fusion inhibitor sensitivity of these envelopes. Clarification
of these non-mutually exclusive possibilities will require
further investigation.
Conclusion
As expected, we found that envelope genes cluster
according to the tissue of origin and the presence of amino
acid changes in brain-derived gp120 envelope glycoproteins
that might be related with higher affinity in the interaction
with CD4. We indeed found that brain-derived envelopes have
lower CD4, but not CCR5, dependence and reduced
sensitivity to inhibition by anti-CD4 MAbs and the fusion
inhibitor T-1249, but not by the CCR5 antagonist TAK-779.
In the absence of different interaction with CCR5, it is
possible that a set of amino acid changes in the HR2 region of
gp41e in the brain-derived envelopes might be involved in the
acquisition of reduced sensitivity to the fusion inhibitor. The
presence of envelopes with this feature in the brain, but not in
the spleen, of an untreated HIV-1 patient is also intriguing.
Fusion inhibitors do not have a good CNS penetration, but
our results seem to indicate that even developing fusion
inhibitors with better CNS penetration might not achieve
antiviral activity within the CNS if, for as yet unknown
reasons, viruses with significantly less sensitive envelopes are
already present in this compartment.
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Tissues and cells
Brain and spleen tissues collected at autopsy from an HIV-1-
positive, untreated individual were kindly provided by Dr.
Benjamin Gelman (Texas NeuroAIDS Research Center, Uni-
versity of Texas Medical Branch, Galveston, TX) and were
obtained through a request to the National NeuroAIDS Tissue
Consortium. Pathological examination of the brain had
confirmed the presence of giant-cell encephalitis consistent
with HIV-1 infection.
Quail QT6 cells were maintained in DMEM supplemented
with 10% heat-inactivated fetal bovine serum, glutamine, and
antibiotics.
Envelope amplification, cloning, and expression
Total DNA was isolated from tissue samples using the
DNeasy Tissue kit (Qiagen, Valencia, CA). Envelope genes
were amplified by PCR as previously described (Shieh et al.,
2000) and cloned into a cloning vector (pCR-XL-Topo,
Invitrogen, Carlsbad, CA). The clones were sequenced at the
Sequencing Core of the University of Pennsylvania, and
sequence alignment and phylogenetic reconstruction were
performed using the Discovery Studio Gene software package
(Accelrys Inc., San Diego, CA). The complete envelope
sequences have been deposited in GenBank (accession
numbers DQ222210–DQ222221). We then subcloned the
envelope clones into the mammalian expression vector
pcDNA3.1 (Invitrogen).
Envelope expression was evaluated in lysates of transiently
transfected cells by immunoassay. Briefly, we immobilized the
sheep polyclonal D7324 Ab (Aalto BioReagents, Dublin,
Ireland) overnight at 4 -C and applied cell lysates for 2 h at
room temperature. Subsequently, we detected the presence of
envelope either with the human anti-CD4i epitope 17b MAb
(1Ag/ml; obtained from James Robinson through the National
Institutes of Health AIDS Research and Reference Reagent
Program [NIH ARRRP]) in combination with excess soluble
CD4 (5 Ag/ml; PerkinElmer, Boston, MA), or the human anti-
CD4 binding site IgG1 b12 MAb (1 Ag/ml; obtained from
Dennis Burton and Carlos Barbas through the NIH ARRRP),
followed by peroxidase-conjugated goat anti-human IgG and
TMB as substrate. Results are expressed as optical density at
690 nm.
Fusion experiments
Cell-to-cell fusion assays were used to test for receptor
utilization, fusogenicity, and sensitivity to Abs and various
inhibitors. Briefly, 106 QT6 effector cells per well in 6-well
plates were infected with 10 pfu/cell of the recombinant
vaccinia virus vTF1.1 that expresses the bacteriophage T7
RNA polymerase (Fuerst et al., 1986) for 1–2 h at 37 -C. After
removing the inoculum and washing with phosphate-buffered
saline (PBS), DMEM supplemented with rifampicin wasadded, and the cells were subsequently transfected by calcium
phosphate precipitation (ProFection Mammalian Transfection
System, Promega, Madison, WI) with 5 Ag DNA of either
envelope expression vector or empty vector as a negative
control. After 4 h at 37 -C, the cells were washed, DMEM with
rifampicin was added, and the cells were incubated overnight at
32 -C. At the same time, 106 QT6 target cells per well in 6-well
plates were transiently transfected with 5 Ag DNA of each CD4
and co-receptor expression vectors, or CD4 plus empty vector
as negative control, and 2 Ag of a luciferase-expression vector
where the luciferase gene is under the control of T7 promoter,
for 6 h at 37 -C. DNA was then removed, and cells were re-
plated into 96-well plates and incubated at 37 -C overnight.
The next day, effector cells were collected, overlaid onto target
cells, and incubated for 5–6 h at 37 -C. Luciferase expression
(indicative of fusion) was detected in cell lysates with a
Luciferase assay kit (Promega) as previously described (Martı´n
et al., 2001) and measured using a LumiCount microplate
luminometer (Packard, Meriden, CT). At least two independent
experiments were performed, with samples at least in triplicate
within each experiment. Results were obtained as relative light
units per second.
To test for CD4 and CCR5 dependencies, cells were
transfected with varying amounts of the corresponding
expression vectors, using empty vector to equilibrate the total
amount of DNA used per well. The levels of expression of
CD4 and CCR5 in the surface of transfected cells were
evaluated by collecting the cells, fixing them with 2%
paraformaldehyde in PBS, followed by blocking with 8%
serum in PBS, and staining with PE-conjugated anti-CD4 clone
RPA-T4 (eBioscience, San Diego, CA) or isotype control
(Caltag, Burlingame, CA) Abs, and FITC-conjugated anti-
CCR5 2D7 (BD Biosciences, San Diego, CA) or isotype
control (BD Biosciences) Abs, respectively. Fluorescence was
measured by flow cytometry in a Calibur instrument (BD,
Franklin Lakes, NJ), and data were analyzed with FlowJo
software (Tree Star Inc., Ashland, OR).
In the experiments testing for sensitivity to inhibition by
anti-CD4 antibodies, we incubated target cells with various
concentrations of RPA-T4 (eBioscience), SK3 (BD Bio-
sciences) and #21 (kindly provided by James Hoxie, University
of Pennsylvania) anti-CD4 MAbs, or mouse IgG as negative
control, for 1 h at 4 -C, before overlaying with effector cells. In
the experiments testing for sensitivity to the CCR5 co-receptor
antagonist TAK-779, target cells were incubated with various
concentrations for 1 h at 37 -C, before overlaying with effector
cells. When testing for sensitivity to the fusion inhibitor T-
1249, effector cells were incubated with various concentrations
of inhibitor (kindly provided by Roche, Palo Alto, CA) for 1
h at 37 -C and subsequently added onto target cells. Finally, the
fusogenicity of different envelopes was evaluated by lysing co-
cultures of effector and target cells at various time points
between 30 min and 6 h.
Fusion levels observed at each Ab/inhibitor concentration
from several experiments (with the value for untreated samples
considered 100%) were used to construct inhibition curves and
were analyzed by non-linear regression with a sigmoidal dose-
J. Martı´n-Garcı´a et al. / Virology 346 (2006) 169–179 177response model (variable slopes) using GraphPad Prism
software, version 4.02 (GraphPad Software, San Diego, CA).
Non-linear regression analysis allowed us to estimate the 50%
inhibitory concentrations (IC50), which were also compared by
Student’s t test.
Acknowledgments
We are grateful to Benjamin Gelman (University of Texas
Medical Branch), the National NeuroAIDS Tissue Consortium,
James Hoxie (University of Pennsylvania) and Roche–Palo
Alto for providing materials and reagents. We thank Samantha
Soldan and Dennis Kolson for their comments on the
manuscript and Anna Waszkiewicz and Shailja Patel for their
technical help.
This work was supported by the National Institutes of
Health grants NS-47970 (to JMG) and NS-27405, NS-35743,
and MH-067734 (to FGS).
Appendix A. Supplementary data
Supplementary data associated with this article can be found
in the online version at doi:10.1016/j.virol.2005.10.031.References
Albright, A.V., Shieh, J.T., Itoh, T., Lee, B., Pleasure, D., O’Connor, M.J.,
Doms, R.W., Gonza´lez-Scarano, F., 1999. Microglia express CCR5,
CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for
human immunodeficiency virus type 1 dementia isolates. J. Virol. 73,
205–213.
Aloisi, F., Ria, F., Adorini, L., 2000. Regulation of T-cell responses by CNS
antigen-presenting cells: different roles for microglia and astrocytes.
Immunol. Today 21, 141–147.
An, S.F., Groves, M., Gray, F., Scaravilli, F., 1999. Early entry and widespread
cellular involvement of HIV-1 DNA in brains of HIV-1 positive
asymptomatic individuals. J. Neuropathol. Exp. Neurol. 58, 1156–1162.
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y.,
Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., Meguro, K., Fujino,
M., 1999. A small-molecule, nonpeptide CCR5 antagonist with highly
potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 96,
5698–5703.
Baribaud, F., Edwards, T.G., Sharron, M., Brelot, A., Heveker, N., Price, K.,
Mortari, F., Alizon, M., Tsang, M., Doms, R.W., 2001. Antigenically
distinct conformations of CXCR4. J. Virol. 75, 8957–8967.
Carson, M.J., Reilly, C.R., Sutcliffe, J.G., Lo, D., 1998. Mature microglia
resemble immature antigen-presenting cells. Glia 22, 72–85.
Chan, D.C., Fass, D., Berger, J.M., Kim, P.S., 1997. Core structure of gp41
from the HIV envelope glycoprotein. Cell 89, 263–273.
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.D., Wu, L.,
Mackay, C.R., LaRosa, G., Newman, W., Gerard, N., Gerard, C., Sodroski,
J., 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection
by primary HIV-1 isolates. Cell 85, 1135–1148.
Davis, L.E., Hjelle, B.L., Miller, V.E., Palmer, D.L., Llewellyn, A.L., Merlin,
T.L., Young, S.A., Mills, R.G., Wachsman, W., Wiley, C.A., 1992. Early
viral brain invasion in iatrogenic human immunodeficiency virus infection.
Neurology 42, 1736–1739.
Derdeyn, C.A., Decker, J.M., Sfakianos, J.N., Wu, X., O’Brien, W.A., Ratner,
L., Kappes, J.C., Shaw, G.M., Hunter, E., 2000. Sensitivity of human
immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated
by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74,
8358–8367.Derdeyn, C.A., Decker, J.M., Sfakianos, J.N., Zhang, Z., O’Brien, W.A.,
Ratner, L., Shaw, G.M., Hunter, E., 2001. Sensitivity of human immuno-
deficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad
repeat involves distinct regions of gp41 and is consistently modulated by
gp120 interactions with the coreceptor. J. Virol. 75, 8605–8614.
Dick, A.D., Pell, M., Brew, B.J., Foulcher, E., Sedgwick, J.D., 1997. Direct ex
vivo flow cytometric analysis of human microglial cell CD4 expression:
examination of central nervous system biopsy specimens from HIV-
seropositive patients and patients with other neurological disease. AIDS
11, 1699–1708.
Doranz, B.J., Rucker, J., Yi, Y., Smyth, R.J., Samson, M., Peiper, S.C.,
Parmentier, M., Collman, R.G., Doms, R.W., 1996. A dual-tropic primary
HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5,
CKR-3, and CKR-2b as fusion cofactors. Cell 85, 1149–1158.
Dorn, J., Masciotra, S., Yang, C., Downing, R., Biryahwaho, B., Mastro, T.D.,
Nkengasong, J., Pieniazek, D., Rayfield, M.A., Hu, D.J., Lal, R.B., 2000.
Analysis of genetic variability within the immunodominant epitopes of
envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group
M and its impact on HIV-1 antibody detection. J. Clin. Microbiol. 38,
773–780.
Dragic, T., Trkola, A., Thompson, D.A., Cormier, E.G., Kajumo, F.A.,
Maxwell, E., Lin, S.W., Ying, W., Smith, S.O., Sakmar, T.P., Moore, J.P.,
2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within
the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U.S.A. 97,
5639–5644.
Epstein, L.G., Kuiken, C., Blumberg, B.M., Hartman, S., Sharer, L.R.,
Clement, M., Goudsmit, J., 1991. HIV-1 V3 domain variation in brain
and spleen of children with AIDS: tissue-specific evolution within host-
determined quasispecies. Virology 180, 583–590.
Eron, J.J., Gulick, R.M., Bartlett, J.A., Merigan, T., Arduino, R., Kilby, J.M.,
Yangco, B., Diers, A., Drobnes, C., DeMasi, R., Greenberg, M., Melby, T.,
Raskino, C., Rusnak, P., Zhang, Y., Spence, R., Miralles, G.D., 2004. Short-
term safety and antiretroviral activity of T-1249, a second-generation fusion
inhibitor of HIV. J. Infect. Dis. 189, 1075–1083.
Fuerst, T.R., Niles, E.G., Studier, F.W., Moss, B., 1986. Eukaryotic transient-
expression system based on recombinant vaccinia virus that synthesizes
bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 83,
8122–8126.
Gonza´lez-Scarano, F., Martı´n-Garcı´a, J., 2005. The neuropathogenesis of
AIDS. Nat. Rev., Immunol. 5, 69–81.
Gorry, P.R., Bristol, G., Zack, J.A., Ritola, K., Swanstrom, R., Birch, C.J., Bell,
J.E., Bannert, N., Crawford, K., Wang, H., Schols, D., De Clercq, E.,
Kunstman, K., Wolinsky, S.M., Gabuzda, D., 2001. Macrophage tropism of
human immunodeficiency virus type 1 isolates from brain and lymphoid
tissues predicts neurotropism independent of coreceptor specificity. J. Virol.
75, 10073–10089.
Gorry, P.R., Taylor, J., Holm, G.H., Mehle, A., Morgan, T., Cayabyab, M.,
Farzan, M., Wang, H., Bell, J.E., Kunstman, K., Moore, J.P., Wolinsky,
S.M., Gabuzda, D., 2002. Increased CCR5 affinity and reduced CCR5/CD4
dependence of a neurovirulent primary human immunodeficiency virus type
1 isolate. J. Virol. 76, 6277–6292.
Hanna, S.L., Yang, C., Owen, S.M., Lal, R.B., 2002. Variability of critical
epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in
HIV-infected populations worldwide [corrected]. AIDS 16, 1603–1608.
He, J., Chen, Y., Farzan, M., Choe, H., Ohagen, A., Gartner, S., Busciglio, J.,
Yang, X., Hofmann, W., Newman, W., Mackay, C.R., Sodroski, J.,
Gabuzda, D., 1997. CCR3 and CCR5 are co-receptors for HIV-1 infection
of microglia. Nature 385, 645–649.
Heil, M.L., Decker, J.M., Sfakianos, J.N., Shaw, G.M., Hunter, E., Derdeyn,
C.A., 2004. Determinants of human immunodeficiency virus type 1
baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside
outside the peptide interaction site. J. Virol. 78, 7582–7589.
Hickey, W.F., Vass, K., Lassmann, H., 1992. Bone marrow-derived elements in
the central nervous system: an immunohistochemical and ultrastructural
survey of rat chimeras. J. Neuropathol. Exp. Neurol. 51, 246–256.
Jordan, C.A., Watkins, B.A., Kufta, C., Dubois-Dalcq, M., 1991. Infection of
brain microglial cells by human immunodeficiency virus type 1 is CD4
dependent. J. Virol. 65, 736–742.
J. Martı´n-Garcı´a et al. / Virology 346 (2006) 169–179178Kilby, J.M., Eron, J.J., 2003. Novel therapies based on mechanisms of HIV-1
cell entry. N. Engl. J. Med. 348, 2228–2238.
Kliger, Y., Gallo, S.A., Peisajovich, S.G., Munoz-Barroso, I., Avkin, S.,
Blumenthal, R., Shai, Y., 2001. Mode of action of an antiviral peptide
from HIV-1. Inhibition at a post-lipid mixing stage. J. Biol. Chem. 276,
1391–1397.
Kodama, T., Mori, K., Kawahara, T., Ringler, D.J., Desrosiers, R.C., 1993.
Analysis of simian immunodeficiency virus sequence variation in tissues of
rhesus macaques with simian AIDS. J. Virol. 67, 6522–6534.
Korber, B.T., Kunstman, K.J., Patterson, B.K., Furtado, M., McEvilly, M.M.,
Levy, R., Wolinsky, S.M., 1994. Genetic differences between blood- and
brain-derived viral sequences from human immunodeficiency virus type 1-
infected patients: evidence of conserved elements in the V3 region of the
envelope protein of brain-derived sequences. J. Virol. 68, 7467–7481.
Krall, W.J., Challita, P.M., Perlmutter, L.S., Skelton, D.C., Kohn, D.B., 1994.
Cells expressing human glucocerebrosidase from a retroviral vector
repopulate macrophages and central nervous system microglia after murine
bone marrow transplantation. Blood 83, 2737–2748.
LaBranche, C.C., Galasso, G., Moore, J.P., Bolognesi, D.P., Hirsch, M.S.,
Hammer, S.M., 2001. HIV fusion and its inhibition. Antiviral Res. 50,
95–115.
Lalezari, J.P., Bellos, N.C., Sathasivam, K., Richmond, G.J., Cohen, C.J.,
Myers Jr., R.A., Henry, D.H., Raskino, C., Melby, T., Murchison, H.,
Zhang, Y., Spence, R., Greenberg, M.L., Demasi, R.A., Miralles, G.D.,
2005. T-1249 retains potent antiretroviral activity in patients who had
experienced virological failure while on an enfuvirtide-containing treatment
regimen. J. Infect. Dis. 191, 1155–1163.
Lee, B., Sharron, M., Blanpain, C., Doranz, B.J., Vakili, J., Setoh, P., Berg,
E., Liu, G., Guy, H.R., Durell, S.R., Parmentier, M., Chang, C.N., Price,
K., Tsang, M., Doms, R.W., 1999a. Epitope mapping of CCR5 reveals
multiple conformational states and distinct but overlapping structures
involved in chemokine and coreceptor function. J. Biol. Chem. 274,
9617–9626.
Lee, B., Sharron, M., Montaner, L.J., Weissman, D., Doms, R.W., 1999b.
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets,
dendritic cells, and differentially conditioned monocyte-derived macro-
phages. Proc. Natl. Acad. Sci. U.S.A. 96, 5215–5220.
Lustig, S., Halevy, M., Ben-Nathan, D., Rice, C.M., Kobiler, D., 1999. The role
of host immunocompetence in neuroinvasion of Sindbis virus. Arch. Virol.
144, 1159–1171.
Martı´n, J., LaBranche, C.C., Gonza´lez-Scarano, F., 2001. Differential
CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity
between envelopes from a microglia-adapted human immunodeficiency
virus type 1 and its parental isolate. J. Virol. 75, 3568–3580.
Martı´n-Garcı´a, J., Kolson, D.L., Gonza´lez-Scarano, F., 2002. Chemokine
receptors in the brain: their role in HIV infection and pathogenesis. AIDS
16, 1709–1730.
Martı´n-Garcı´a, J., Cocklin, S., Chaiken, I.M., Gonza´lez-Scarano, F., 2005.
Interaction with CD4 and antibodies to CD4-induced epitopes of the
envelope gp120 from a microglial cell-adapted human immunodeficiency
virus type 1 isolate. J. Virol. 79, 6703–6713.
McArthur, J.C., Haughey, N., Gartner, S., Conant, K., Pardo, C., Nath, A.,
Sacktor, N., 2003. Human immunodeficiency virus-associated dementia: an
evolving disease. J. NeuroVirol. 9, 205–221.
Menzo, S., Castagna, A., Monachetti, A., Hasson, H., Danise, A., Carini, E.,
Bagnarelli, P., Lazzarin, A., Clementi, M., 2004. Genotype and phenotype
patterns of human immunodeficiency virus type 1 resistance to enfuvir-
tide during long-term treatment. Antimicrob. Agents Chemother. 48,
3253–3259.
Neil, S.J., Aasa-Chapman, M.M., Clapham, P.R., Nibbs, R.J., McKnight, A.,
Weiss, R.A., 2005. The promiscuous CC chemokine receptor D6 is a
functional coreceptor for primary isolates of human immunodeficiency
virus type 1 (HIV-1) and HIV-2 on astrocytes. J. Virol. 79, 9618–9624.
Ohagen, A., Devitt, A., Kunstman, K.J., Gorry, P.R., Rose, P.P., Korber, B.,
Taylor, J., Levy, R., Murphy, R.L., Wolinsky, S.M., Gabuzda, D., 2003.
Genetic and functional analysis of full-length human immunodeficiency
virus type 1 env genes derived from brain and blood of patients with AIDS.
J. Virol. 77, 12336–12345.Peters, P.J., Bhattacharya, J., Hibbitts, S., Dittmar, M.T., Simmons, G., Bell,
J., Simmonds, P., Clapham, P.R., 2004. Biological analysis of human
immunodeficiency virus type 1 R5 envelopes amplified from brain and
lymph node tissues of AIDS patients with neuropathology reveals two
distinct tropism phenotypes and identifies envelopes in the brain that
confer an enhanced tropism and fusigenicity for macrophages. J. Virol. 78,
6915–6926.
Peudenier, S., Hery, C., Montagnier, L., Tardieu, M., 1991a. Human microglial
cells: characterization in cerebral tissue and in primary culture, and study of
their susceptibility to HIV-1 infection. Ann. Neurol. 29, 152–161.
Peudenier, S., Hery, C., Ng, K.H., Tardieu, M., 1991b. HIV receptors within the
brain: a study of CD4 and MHC-II on human neurons, astrocytes and
microglial cells. Res. Virol. 142, 145–149.
Reddy, R.T., Achim, C.L., Sirko, D.A., Tehranchi, S., Kraus, F.G., Wong-
Staal, F., Wiley, C.A., 1996. Sequence analysis of the V3 loop in brain
and spleen of patients with HIV encephalitis. AIDS Res. Hum. Retrovir.
12, 477–482.
Reeves, J.D., Gallo, S.A., Ahmad, N., Miamidian, J.L., Harvey, P.E., Sharron,
M., Pohlmann, S., Sfakianos, J.N., Derdeyn, C.A., Blumenthal, R., Hunter,
E., Doms, R.W., 2002. Sensitivity of HIV-1 to entry inhibitors correlates
with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Proc. Natl. Acad. Sci. U.S.A. 99, 16249–16254.
Reeves, J.D., Miamidian, J.L., Biscone, M.J., Lee, F.H., Ahmad, N., Pierson,
T.C., Doms, R.W., 2004. Impact of mutations in the coreceptor binding site
on human immunodeficiency virus type 1 fusion, infection, and entry
inhibitor sensitivity. J. Virol. 78, 5476–5485.
Rimsky, L.T., Shugars, D.C., Matthews, T.J., 1998. Determinants of human
immunodeficiency virus type 1 resistance to gp41-derived inhibitory
peptides. J. Virol. 72, 986–993.
Rottman, J.B., Ganley, K.P., Williams, K., Wu, L., Mackay, C.R., Ringler, D.J.,
1997. Cellular localization of the chemokine receptor CCR5. Correlation to
cellular targets of HIV-1 infection. Am. J. Pathol. 151, 1341–1351.
Sacktor, N., McDermott, M.P., Marder, K., Schifitto, G., Selnes, O.A.,
McArthur, J.C., Stern, Y., Albert, S., Palumbo, D., Kieburtz, K., De
Marcaida, J.A., Cohen, B., Epstein, L., 2002. HIV-associated cognitive
impairment before and after the advent of combination therapy.
J. NeuroVirol. 8, 136–142.
Sanders, R.W., Korber, B., Lu, M., Berkhout, B., Moore, J.P., 2002. Mutational
analyses and natural variability of the gp41 ectodomain. In: Kuiken, C.,
Foley, B., Freed, E., Hahn, B., Korber, B., Marx, P.A., McCutchan, F.,
Mellors, J.W., Wolinksy, S. (Eds.), HIV Sequence Compendium 2002.
Theoretical Biology and Biophysics Group. Los Alamos National Labora-
tory, Los Alamos, NM, pp. 43–68.
Sharer, L.R., Cho, E.S., Epstein, L.G., 1985. Multinucleated giant cells and
HTLV-III in AIDS encephalopathy. Hum. Pathol. 16, 760.
Sharer, L.R., Epstein, L.G., Cho, E.S., Joshi, V.V., Meyenhofer, M.F., Rankin,
L.F., Petito, C.K., 1986. Pathologic features of AIDS encephalopathy in
children: evidence for LAV/HTLV-III infection of brain. Hum. Pathol. 17,
271–284.
Shieh, J.T., Martı´n, J., Baltuch, G., Malim, M.H., Gonza´lez-Scarano, F.,
2000. Determinants of syncytium formation in microglia by human
immunodeficiency virus type 1: role of the V1/V2 domains. J. Virol. 74,
693–701.
Springael, J.Y., Urizar, E., Parmentier, M., 2005. Dimerization of chemokine
receptors and its functional consequences. Cytokine Growth Factor Rev. 16,
611–623.
Strizki, J.M., Albright, A.V., Sheng, H., O’Connor, M., Perrin, L., Gonzalez-
Scarano, F., 1996. Infection of primary human microglia and monocyte-
derived macrophages with human immunodeficiency virus type 1 isolates:
evidence of differential tropism. J. Virol. 70, 7654–7662.
Tuttle, D.L., Harrison, J.K., Anders, C., Sleasman, J.W., Goodenow, M.M.,
1998. Expression of CCR5 increases during monocyte differentiation and
directly mediates macrophage susceptibility to infection by human
immunodeficiency virus type 1. J. Virol. 72, 4962–4969.
Unger, E.R., Sung, J.H., Manivel, J.C., Chenggis, M.L., Blazar, B.R., Krivit,
W., 1993. Male donor-derived cells in the brains of female sex-mismatched
bone marrow transplant recipients: a Y-chromosome specific in situ
hybridization study. J. Neuropathol. Exp. Neurol. 52, 460–470.
J. Martı´n-Garcı´a et al. / Virology 346 (2006) 169–179 179van der Meer, P., Ulrich, A.M., Gonzalez-Scarano, F., Lavi, E., 2000.
Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in
the human brain: potential mechanisms for HIV dementia. Exp. Mol.
Pathol. 69, 192–201.
Wei, X., Decker, J.M., Liu, H., Zhang, Z., Arani, R.B., Kilby, J.M., Saag,
M.S., Wu, X., Shaw, G.M., Kappes, J.C., 2002. Emergence of
resistant human immunodeficiency virus type 1 in patients receiving
fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46,
1896–1905.
Westmoreland, S.V., Rottman, J.B., Williams, K.C., Lackner, A.A., Sasseville,
V.G., 1998. Chemokine receptor expression on resident and inflammatory
cells in the brain of macaques with simian immunodeficiency virus
encephalitis. Am. J. Pathol. 152, 659–665.
Wiley, C.A., Schrier, R.D., Nelson, J.A., Lampert, P.W., Oldstone, M.B., 1986.
Cellular localization of human immunodeficiency virus infection within the
brains of acquired immune deficiency syndrome patients. Proc. Natl. Acad.
Sci. U.S.A. 83, 7089–7093.Wong, J.K., Ignacio, C.C., Torriani, F., Havlir, D., Fitch, N.J., Richman,
D.D., 1997. In vivo compartmentalization of human immunodeficiency
virus: evidence from the examination of pol sequences from autopsy
tissues. J. Virol. 71, 2059–2071.
Wu, L., Paxton, W.A., Kassam, N., Ruffing, N., Rottman, J.B., Sullivan, N.,
Choe, H., Sodroski, J., Newman, W., Koup, R.A., Mackay, C.R., 1997.
CCR5 levels and expression pattern correlate with infectability by
macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185, 1681–1691.
Xia, M.Q., Qin, S.X., Wu, L.J., Mackay, C.R., Hyman, B.T., 1998.
Immunohistochemical study of the beta-chemokine receptors CCR3 and
CCR5 and their ligands in normal and Alzheimer’s disease brains. Am. J.
Pathol. 153, 31–37.
Xu, L., Pozniak, A., Wildfire, A., Stanfield-Oakley, S.A., Mosier, S.M.,
Ratcliffe, D., Workman, J., Joall, A., Myers, R., Smit, E., Cane, P.A.,
Greenberg, M.L., Pillay, D., 2005. Emergence and evolution of enfuvirtide
resistance following long-term therapy involves heptad repeat 2 mutations
within gp41. Antimicrob. Agents Chemother. 49, 1113–1119.
